Zepbound, sleep apnea and Food and Drug Administration

FDA approves weight-loss drug Zepbound to treat sleep apnea
The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, making it the first medication for certain patients with the condition.
Weight loss drug Zepbound approved to help sleep apnea patients
( NewsNation) — Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea in obese adults earlier this month.
The popular weight-loss drug Zepbound can now be used to treat sleep apnea
The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity.
Zepbound Weight Loss Medication Approved by FDA to Treat Sleep Apnea
The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as tirzepatide, to help people treat obstructive sleep apnea.
FDA approves weight-loss drug Zepbound for obstructive sleep apnea
The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the weight-loss drug Zepbound.
FDA: Weight loss drug Zepbound, diabetes drug Mounjaro no longer in shortage
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for these medications.
FDA approves Zepbound for sleep apnea in obese adults
Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, although it is not a cure and requires weight loss to be maintained over time.
FDA approves new drug for sleep apnea
The drug is known as Zepbound and is the same as the chemical drug Tirzepatide. "See To Believe uncovers the forgotten, mind-blowing facts that will leave you questioning everything. Follow wild stories of mysterious creatures,
Weight-loss drug investments: why 2025 could be a game-changer
Biopharmaceutical firms engaged in developing weight-loss drugs were rewarded rather significantly in 2024. It’s what helped ...
CNN27d
Zepbound leads to more weight loss than Wegovy, drugmaker Eli Lilly says
That translates to an average weight loss of about 50 pounds for those taking Zepbound, compared with an average weight loss of 33 pounds for those taking Wegovy. People taking Zepbound ...
Yahoo21d
Is Zepbound or Wegovy Better for Weight Loss? One Can Help You Shed 50 Lbs
The findings? Zepbound led to an average weight loss of 20.2 percent compared to Wegovy's 13.7 percent. We talked with healthcare experts to understand the study’s findings, what sets these ...
Medical News Today21d
Average weight loss on Zepbound
Zepbound helps aid weight loss. Research consistently suggests people with overweight or obesity have more average weight loss on Zepbound than a placebo. The active ingredient in ...
UPI27d
In new trial, Zepbound bests Wegovy for weight loss
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly. "Given the increased interest around obesity ...
ABC News27d
Zepbound leads to more weight loss than Wegovy, Eli Lilly says
While both medications showed a significant weight loss benefit, after 72 weeks on treatment, people treated with Zepbound lost 20% of their body weight, compared to people on Wegovy who lost ...
Yahoo1d
2024 was the year of weight loss for Floridians. Wondering why?
There are currently three medications (GLP-1s) on the market that the FDA has specifically approved to treat obesity — Wegovy ...